Verve pauses lead base editing program after safety event, switches focus to follow-up candidate near clinic
02 Apr 2024
Gene TherapyPhase 3
Verve Therapeutics is pausing work on its lead gene editing treatment, which was the
first time
base editing was used to directly alter DNA in humans, after a serious adverse event. The biotech will turn its focus to a similar candidate with a different type of lipid delivery.
The Boston biotech will pause enrollment in its Heart-1 trial of VERVE-101 after a patient experienced a grade 3 drug-induced transient increase in serum alanine aminotransferase, Verve said before the markets opened on Tuesday. The patient also had a grade 3 drug-induced thrombocytopenia or low level of platelet in the blood, and the “abnormalities resolved fully within a few days,” the drug developer said.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.